{"id":5877,"date":"2023-05-15T07:30:29","date_gmt":"2023-05-15T11:30:29","guid":{"rendered":"https:\/\/bridge-bio.local\/news\/auto-draft\/"},"modified":"2023-05-12T17:31:08","modified_gmt":"2023-05-12T21:31:08","slug":"bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting","status":"publish","type":"post","link":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/","title":{"rendered":"BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting"},"content":{"rendered":"<p><b><span data-contrast=\"none\">PALO ALTO, CA \u2013 May 15, 2022\u202f\u2014 <\/span><\/b><span data-contrast=\"auto\">BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d),\u202fa commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that updated data from CAN<\/span><i><span data-contrast=\"auto\">aspire<\/span><\/i><span data-contrast=\"auto\">, its Phase 1\/2 clinical trial of BBP-812, an investigational intravenous (IV) adeno-associated virus serotype 9 (AAV9) gene therapy for the treatment of Canavan disease, will be presented at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place in Los Angeles, CA on May 16 \u2013 20, 2023.<\/span><\/p>\n<p>Additionally, members of BridgeBio leadership, including Neil Kumar, CEO and founder, will be presenting on multiple panels discussing drug development and accelerated approval for gene therapy.<\/p>\n<p><span style=\"text-decoration: underline;\"><b>Oral presentation details:<\/b>\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Initial biomarker and clinical findings from the CAN<\/span><\/b><b><i><span data-contrast=\"auto\">aspire<\/span><\/i><\/b><b><span data-contrast=\"auto\"> Canavan disease gene therapy trial: Exploration of connections between NAA and disease severity<\/span><\/b><br \/>\n<b><\/b><\/p>\n<p><b><span data-contrast=\"auto\">Presenter: <\/span><\/b><span data-contrast=\"auto\">Florian Eichler, M.D., director of the leukodystrophy service at Massachusetts General Hospital, Center for Rare Neurological Disease and lead CAN<\/span><i><span data-contrast=\"auto\">aspire<\/span><\/i><span data-contrast=\"auto\"> investigator<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Session date\/ time: <\/span><\/b><span data-contrast=\"auto\">Saturday, May 20 at 10:15 am \u2013 12:00 pm PT<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Presentation time: <\/span><\/b><span data-contrast=\"auto\">11:15 am \u2013 11:30 am PT<\/span><br \/>\n<b><span data-contrast=\"auto\">Location: <\/span><\/b><span data-contrast=\"auto\">Concourse Hall 150 &amp; 151, Los Angeles Convention Center<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Session title: <\/span><\/b><span data-contrast=\"auto\">Gene and cell therapy trials in progress<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Abstract number: <\/span><\/b><span data-contrast=\"auto\">358<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span style=\"text-decoration: underline;\"><b>Additional panel details:<\/b><\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Accelerated approval for cell and gene therapies<\/span><\/b><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Date &amp; time:<\/span><\/b><span data-contrast=\"auto\"> Wednesday, May 17 at 9:00 am \u2013 9:45 am PT<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Panelist:<\/span><\/b><span data-contrast=\"auto\"> Adora Ndu, Pharm.D., J.D., chief regulatory and interim legal officer of BridgeBio<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Location: <\/span><\/b><span data-contrast=\"auto\">Room 515 AB<\/span><span data-contrast=\"auto\">, Los Angeles Convention Center<\/span><br \/>\n<span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Venture capital in the gene and cell therapy space<\/span><\/b><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Date &amp; time:<\/span><\/b><span data-contrast=\"auto\"> Friday, May 19 at 8:00 am \u2013 9:45 am PT<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Co-chair: <\/span><\/b><span data-contrast=\"auto\">Eric David, M.D., J.D., CEO of BridgeBio Gene Therapy<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Panelist:<\/span><\/b><span data-contrast=\"auto\"> Neil Kumar, Ph.D., founder and CEO of BridgeBio<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Location: <\/span><\/b><span data-contrast=\"auto\">Concourse Hall 152 &amp; 153<\/span><span data-contrast=\"auto\">, Los Angeles Convention Center<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"none\">Evolution of genetic medicines: Navigating the challenges and synergies among therapeutic modalities<\/span><\/b><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Date &amp; time: <\/span><\/b><span data-contrast=\"auto\">Friday, May 19 at 10:15 am \u2013 12:30 pm PT\u00a0<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Panelist:<\/span><\/b><span data-contrast=\"auto\"> Eric David, M.D., J.D., CEO of BridgeBio Gene Therapy<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Location: <\/span><\/b><span data-contrast=\"auto\">Room 411, Los Angeles Convention Center<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Accelerate your drug development program in rare disease with robust natural history data: An evolving space<\/span><\/b><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Session title: <\/span><\/b><span data-contrast=\"none\">How to design a natural history study that regulators and clinicians support<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Date &amp; time:<\/span><\/b><span data-contrast=\"auto\"> Friday, May 19 at <\/span><span data-contrast=\"none\">10:15 am \u2013 12:00 pm PT<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Panelist:<\/span><\/b><span data-contrast=\"auto\"> Adam Shaywitz, M.D., Ph.D., chief medical officer at BridgeBio Gene Therapy<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Location: <\/span><\/b><span data-contrast=\"auto\">Room 408 AB, Los Angeles Convention Center<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">About BridgeBio Pharma, Inc.<\/span><\/b><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">BridgeBio Pharma Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio\u2019s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers, and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit \u202f<\/span><a href=\"http:\/\/bridgebio.com\/\"><b><span data-contrast=\"none\">bridgebiodev.wpengine.com<\/span><\/b><\/a><span data-contrast=\"auto\">\u202fand follow us on\u202f<\/span><a href=\"https:\/\/www.linkedin.com\/company\/6824982\/admin\/\"><b><span data-contrast=\"none\">LinkedIn<\/span><\/b><\/a><span data-contrast=\"auto\">\u202fand\u202f<\/span><a href=\"https:\/\/twitter.com\/BridgeBioPharma\"><b><span data-contrast=\"none\">Twitter<\/span><\/b><\/a><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><b><span data-contrast=\"auto\">BridgeBio Media Contact:<\/span><\/b><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Vikram Bali<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">contact@bridgebiodev.wpengine.com\u00a0<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">(650)-789-8220<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PALO ALTO, CA \u2013 May 15, 2022\u202f\u2014 BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d),\u202fa commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that updated data from CANaspire, its Phase 1\/2 clinical trial of BBP-812, an investigational intravenous (IV) adeno-associated virus serotype 9 (AAV9) gene therapy for the treatment of Canavan [&hellip;]<\/p>\n","protected":false},"author":22,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[10],"tags":[],"class_list":["post-5877","post","type-post","status-publish","format-standard","hentry","category-press-release"],"acf":{"people":false,"external_link":"","presentation":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - BridgeBio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - BridgeBio\" \/>\n<meta property=\"og:description\" content=\"PALO ALTO, CA \u2013 May 15, 2022\u202f\u2014 BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d),\u202fa commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that updated data from CANaspire, its Phase 1\/2 clinical trial of BBP-812, an investigational intravenous (IV) adeno-associated virus serotype 9 (AAV9) gene therapy for the treatment of Canavan [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"BridgeBio\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-15T11:30:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-12T21:31:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Kaitlyn Reilly\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:site\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Kaitlyn Reilly\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/\",\"url\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/\",\"name\":\"BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - BridgeBio\",\"isPartOf\":{\"@id\":\"https:\/\/bridgebio.com\/#website\"},\"datePublished\":\"2023-05-15T11:30:29+00:00\",\"dateModified\":\"2023-05-12T21:31:08+00:00\",\"author\":{\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/cd17f1fef87fbb503cdc4095ec5b3c60\"},\"breadcrumb\":{\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bridgebio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/bridgebio.com\/#website\",\"url\":\"https:\/\/bridgebio.com\/\",\"name\":\"BridgeBio\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/bridgebio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/cd17f1fef87fbb503cdc4095ec5b3c60\",\"name\":\"Kaitlyn Reilly\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/589c3adcd55b12c15da3e878a123f424?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/589c3adcd55b12c15da3e878a123f424?s=96&d=mm&r=g\",\"caption\":\"Kaitlyn Reilly\"},\"sameAs\":[\"http:\/\/Dev%20Team\"],\"url\":\"https:\/\/bridgebio.com\/author\/kaitlynreilly\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - BridgeBio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - BridgeBio","og_description":"PALO ALTO, CA \u2013 May 15, 2022\u202f\u2014 BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d),\u202fa commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that updated data from CANaspire, its Phase 1\/2 clinical trial of BBP-812, an investigational intravenous (IV) adeno-associated virus serotype 9 (AAV9) gene therapy for the treatment of Canavan [&hellip;]","og_url":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/","og_site_name":"BridgeBio","article_published_time":"2023-05-15T11:30:29+00:00","article_modified_time":"2023-05-12T21:31:08+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png","type":"image\/png"}],"author":"Kaitlyn Reilly","twitter_card":"summary_large_image","twitter_creator":"@BridgeBioPharma","twitter_site":"@BridgeBioPharma","twitter_misc":{"Written by":"Kaitlyn Reilly","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/","url":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/","name":"BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - BridgeBio","isPartOf":{"@id":"https:\/\/bridgebio.com\/#website"},"datePublished":"2023-05-15T11:30:29+00:00","dateModified":"2023-05-12T21:31:08+00:00","author":{"@id":"https:\/\/bridgebio.com\/#\/schema\/person\/cd17f1fef87fbb503cdc4095ec5b3c60"},"breadcrumb":{"@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bridgebio.com\/"},{"@type":"ListItem","position":2,"name":"BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/bridgebio.com\/#website","url":"https:\/\/bridgebio.com\/","name":"BridgeBio","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bridgebio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/cd17f1fef87fbb503cdc4095ec5b3c60","name":"Kaitlyn Reilly","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/589c3adcd55b12c15da3e878a123f424?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/589c3adcd55b12c15da3e878a123f424?s=96&d=mm&r=g","caption":"Kaitlyn Reilly"},"sameAs":["http:\/\/Dev%20Team"],"url":"https:\/\/bridgebio.com\/author\/kaitlynreilly\/"}]}},"_links":{"self":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/5877"}],"collection":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/users\/22"}],"replies":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/comments?post=5877"}],"version-history":[{"count":0,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/5877\/revisions"}],"wp:attachment":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/media?parent=5877"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/categories?post=5877"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/tags?post=5877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}